FB-101

DRUG2 trials

Sponsors

1ST Biotherapeutics, Inc.

Conditions

HealthyParkinson's Disease

Phase 1

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

CompletedNCT04165837

1ST Biotherapeutics, Inc.Parkinson's Disease

Start: 2019-10-14End: 2022-07-14Updated: 2023-01-26

A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects

Not yet recruitingNCT07126704

1ST Biotherapeutics, Inc.Healthy

Start: 2027-01-01End: 2028-03-01Target: 72Updated: 2026-09-02